AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently recruiting for a Phase 3 clinical trial titled Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS). The study aims to assess the safety, tolerability, and pharmacokinetics of benralizumab, a drug administered subcutaneously every four weeks, in children with rare eosinophilic diseases. This trial is significant as it explores treatment options for pediatric patients with conditions like eosinophilic granulomatosis with polyangiitis (EGPA).
The intervention being tested is benralizumab, a drug designed to treat eosinophilic diseases by reducing eosinophil levels in the body. It is administered as a subcutaneous injection every four weeks.
The study is designed as an open-label, single-group trial with no masking, focusing on treatment as its primary purpose. All participants will receive benralizumab, with the study structured into screening, treatment, and extension periods.
The study began on April 17, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This clinical update could influence AstraZeneca’s stock performance positively if the trial results are favorable, as it addresses a niche market with limited treatment options. Investors should monitor this study’s progress, considering the competitive landscape in the pharmaceutical industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.